If you are starting cancer treatment, you could be at risk for chemotherapy-induced
nausea and vomiting (CINV). You may want to understand your risk before beginning
chemotherapy and discuss CINV with your doctor or nurse.
The leading factor in determining your risk is the type of chemotherapy you receive
and how it is given. However, there are other factors that could also affect your
likelihood of having CINV.
Please take a moment to answer the questions in this survey to assess your risk.
You can print your results and take them with you to your next doctor's visit.
Only your doctor can fully determine if you are at risk for CINV.
Below is a list of possible chemotherapies that may put you at moderate or high
risk for developing chemotherapy-induced nausea and vomiting (CINV).
- AC combination defined as either doxorubicin or epirubicin with cyclophosphamide
- Aldesleukin >12-15 million IU/m2
- Amifostine >300 mg/m2
- Arsenic trioxide
- Azacitidine
- Bendamustine
- Busulfan
- Carboplatin
- Carmustine
- Cisplatin
- Clofarabine
- Cyclophosphamide
|
- Cytarabine >200 mg/m2
- Dacarbazine
- Dactinomycin
- Daunorubicin
- Doxorubicin
- Epirubicin
- Idarubicin
- Ifosfamide
- Interferon alpha ≥10 million IU/m2
- Irinotecan
- Mechlorethamine
- Melphalan
- Methotrexate ≤ 250 mg/m2
- Oxaliplatin
- Streptozocin
- Temozolomide
|
Complete this assessment to determine if there are additional factors that increase
your risk of developing CINV.